SAVA Stock Analysis: Buy, Sell, or Hold?
SAVA - Cassava Sciences, Inc.
$2.38
0.26 (12.26%)
▲
5d:
+7.21%
30d:
+17.24%
90d:
-26.99%
BUY
HIGH Confidence
Analysis Updated: Mar 10, 2026 12:00 AM ET
Earnings: May 07, 2026
Smart Money Distribution
SAVA is up 6.2% this week, but smart money is buying puts. Top strike: $1.5 2026-05-15 with 701 OI. Put ratio: 67% View Scanner →
Strength: 4.8/10
Get Alerted When SAVA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: SAVA shows strong fundamentals and good volume confirmation. Solid entry point despite extended pricing.
✅ BUY SIGNAL: SAVA shows strong fundamentals and good volume confirmation. Solid entry point despite extended pricing.
In-depth Analysis How we analyze
Valuation Analysis: SAVA is currently trading at $2.38, which is considered extended relative to its 30-day fair value range of $2.11 to $2.36.
Technical Outlook: Technically, SAVA is in a strong downtrend. Immediate support is located at $1.96, while resistance sits at $2.49. The stock is showing strong short-term momentum, up 12.3% recently.
Market Sentiment: SAVA has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $8.00 (+236.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, SAVA is in a strong downtrend. Immediate support is located at $1.96, while resistance sits at $2.49. The stock is showing strong short-term momentum, up 12.3% recently.
Market Sentiment: SAVA has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $8.00 (+236.1%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$2.11 -
$2.36
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
75.0%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+12.3%)
- BULLISH: Trading 236.1% below Wall St target ($8.00)
Fair Price Analysis
30-Day Fair Range
$2.11 -
$2.36
Current vs Fair Value
EXTENDED
Expected Move (7 Days)
±$0.28
(11.6%)
Support & Resistance Levels
Support Level
$1.96
Resistance Level
$2.49
Current Trend
Strong Downtrend
Technical data as of
Mar 10, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.95
Wall Street Target
$8.00
(+236.1%)
Share & Embed Analysis
Last updated: April 02, 2026 6:04 AM ET
Data refreshes hourly during market hours. Next update: 7:04 AM
Data refreshes hourly during market hours. Next update: 7:04 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SAVA showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Richard Barry
BUY
73385 shares
2025-11-19
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$21 | 56 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1018 | 55 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$547 | 52 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 59 HOLD |
